Top Story

Boehringer Ingelheim files BLA for antidote to dabigatran

March 2, 2015

Boehringer Ingelheim announced that it has submitted a biologics license application to the FDA requesting an accelerated approval pathway for idarucizumab, an antidote to dabigatran.

In June 2014, the investigational reversal agent received a breakthrough therapy designation from the FDA.

In the Journals

Chronic fungal lesions predisposed to malignancy

March 2, 2015
Researchers in Brazil documented seven cases of squamous cell carcinoma that resulted from chronic chromoblastomycosis in the Brazilian Amazon state…
In the JournalsPerspective

Recursive partitioning analysis forms new stages for HPV-related oropharyngeal cancer

March 2, 2015
Recursive partitioning analysis-based TNM stage groupings were associated with significantly improved survival prediction for patients with HPV-related non-metastatic…
Deepa Bhojwani, MD Institution Notes

Childrens hospital appoints leukemia director

March 1, 2015
Deepa Bhojwani, MD, has been appointed director of the leukemia/lymphoma program at the Children’s Center for Cancer and Blood Diseases, part of Children’s…
Institution Notes

NIH recruits three Lasker scholars

February 28, 2015
The NIH has selected three researchers as new Lasker Clinical Research Scholars as part of a joint initiative with the Albert and Mary Lasker Foundation to nurture the…
More News Headlines »
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
thumbnail for video 4040847621001

MET targeting, PD-L1/PD-1 inhibition highlight recent developments in genitourinary oncology

February 11, 2015
Derek Raghavan, MD, PhD, FACP, FRACP, FASCO, president of Levine Cancer Institute at Carolinas HealthCare System and…
More »
High Risk AAMDS

Treatment Decision-Making through the Spectrum of MDS:
Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »